157 related articles for article (PubMed ID: 36759728)
1. An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer.
Jacob J; Francisco LE; Chatterjee T; Liang Z; Subramanian S; Liu QJ; Rowe JH; Carmon KS
Br J Cancer; 2023 Apr; 128(8):1592-1602. PubMed ID: 36759728
[TBL] [Abstract][Full Text] [Related]
2. GPR56 promotes proliferation of colorectal cancer cells and enhances metastasis via epithelial‑mesenchymal transition through PI3K/AKT signaling activation.
Ji B; Feng Y; Sun Y; Ji D; Qian W; Zhang Z; Wang Q; Zhang Y; Zhang C; Sun Y
Oncol Rep; 2018 Oct; 40(4):1885-1896. PubMed ID: 30066935
[TBL] [Abstract][Full Text] [Related]
3. GPR56 Drives Colorectal Tumor Growth and Promotes Drug Resistance through Upregulation of MDR1 Expression via a RhoA-Mediated Mechanism.
Zhang S; Chatterjee T; Godoy C; Wu L; Liu QJ; Carmon KS
Mol Cancer Res; 2019 Nov; 17(11):2196-2207. PubMed ID: 31444231
[TBL] [Abstract][Full Text] [Related]
4. Anti-GPR56 monoclonal antibody potentiates GPR56-mediated Src-Fak signaling to modulate cell adhesion.
Chatterjee T; Zhang S; Posey TA; Jacob J; Wu L; Yu W; Francisco LE; Liu QJ; Carmon KS
J Biol Chem; 2021; 296():100261. PubMed ID: 33837725
[TBL] [Abstract][Full Text] [Related]
5. Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab.
Benelli R; Costa D; Salvini L; Tardito S; Tosetti F; Villa F; Zocchi MR; Poggi A
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36543375
[TBL] [Abstract][Full Text] [Related]
6. An amino acid transporter subunit as an antibody-drug conjugate target in colorectal cancer.
Montero JC; Del Carmen S; Abad M; Sayagués JM; Barbáchano A; Fernández-Barral A; Muñoz A; Pandiella A
J Exp Clin Cancer Res; 2023 Aug; 42(1):200. PubMed ID: 37559159
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of GPR56 in patients with colorectal cancer.
Lim DR; Kang DH; Kuk JC; Kim TH; Shin EJ; Ahn TS; Kim HJ; Jeong DJ; Baek MJ; Kim NK
Neoplasma; 2021 May; 68(3):580-589. PubMed ID: 33618521
[TBL] [Abstract][Full Text] [Related]
8. TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.
Gymnopoulos M; Betancourt O; Blot V; Fujita R; Galvan D; Lieuw V; Nguyen S; Snedden J; Stewart C; Villicana J; Wojciak J; Wong E; Pardo R; Patel N; D'Hooge F; Vijayakrishnan B; Barry C; Hartley JA; Howard PW; Newman R; Coronella J
Mol Oncol; 2020 Jan; 14(1):54-68. PubMed ID: 31736230
[TBL] [Abstract][Full Text] [Related]
9. Lectin drug conjugate therapy for colorectal cancer.
Kitaguchi D; Oda T; Enomoto T; Ohara Y; Owada Y; Akashi Y; Furuta T; Yu Y; Kimura S; Kuroda Y; Kurimori K; Miyazaki Y; Furuya K; Shimomura O; Tateno H
Cancer Sci; 2020 Dec; 111(12):4548-4557. PubMed ID: 33058342
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer.
Liu H; Zhou D; Liu D; Xu X; Zhang K; Hu R; Xiong P; Wang C; Zeng X; Wang L; Zhang S
Cell Death Dis; 2024 Mar; 15(3):187. PubMed ID: 38443386
[TBL] [Abstract][Full Text] [Related]
11. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy.
Feng L; Yao HP; Wang W; Zhou YQ; Zhou J; Zhang R; Wang MH
Clin Cancer Res; 2014 Dec; 20(23):6045-58. PubMed ID: 25294907
[TBL] [Abstract][Full Text] [Related]
13. CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy.
Khan T; Lyons NJ; Gough M; Kwah KKX; Cuda TJ; Snell CE; Tse BW; Sokolowski KA; Pearce LA; Adams TE; Rose SE; Puttick S; Pajic M; Adams MN; He Y; Hooper JD; Kryza T
Theranostics; 2022; 12(16):6915-6930. PubMed ID: 36276654
[No Abstract] [Full Text] [Related]
14. The G-protein coupled receptor 56, expressed in colonic stem and cancer cells, binds progastrin to promote proliferation and carcinogenesis.
Jin G; Sakitani K; Wang H; Jin Y; Dubeykovskiy A; Worthley DL; Tailor Y; Wang TC
Oncotarget; 2017 Jun; 8(25):40606-40619. PubMed ID: 28380450
[TBL] [Abstract][Full Text] [Related]
15. Antibody-drug Conjugate PCMC1D3-Duocarmycin SA as a Novel Therapeutic Entity for Targeted Treatment of Cancers Aberrantly Expressing MET Receptor Tyrosine Kinase.
Hudson R; Yao HP; Suthe SR; Patel D; Wang MH
Curr Cancer Drug Targets; 2022; 22(4):312-327. PubMed ID: 34951367
[TBL] [Abstract][Full Text] [Related]
16. Lipolysis-stimulated lipoprotein receptor-targeted antibody-drug conjugate demonstrates potent antitumor activity against epithelial ovarian cancer.
Kanda M; Serada S; Hiramatsu K; Funauchi M; Obata K; Nakagawa S; Ohkawara T; Murata O; Fujimoto M; Chiwaki F; Sasaki H; Ueda Y; Kimura T; Naka T
Neoplasia; 2023 Jan; 35():100853. PubMed ID: 36413881
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors.
McDermott MSJ; O'Brien NA; Hoffstrom B; Gong K; Lu M; Zhang J; Luo T; Liang M; Jia W; Hong JJ; Chau K; Davenport S; Xie B; Press MF; Panayiotou R; Handly-Santana A; Brugge JS; Presta L; Glaspy J; Slamon DJ
Clin Cancer Res; 2023 Jun; 29(11):2131-2143. PubMed ID: 36884217
[TBL] [Abstract][Full Text] [Related]
18. Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer.
Nishigaki T; Takahashi T; Serada S; Fujimoto M; Ohkawara T; Hara H; Sugase T; Otsuru T; Saito Y; Tsujii S; Nomura T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Nakajima K; Eguchi H; Yamasaki M; Mori M; Doki Y; Naka T
Br J Cancer; 2020 Apr; 122(9):1333-1341. PubMed ID: 32152502
[TBL] [Abstract][Full Text] [Related]
19. SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models.
Gray E; Ulrich M; Epp A; Younan P; Sahetya D; Hensley K; Allred S; Huang LY; Hahn J; Gahnberg K; Treuting PM; Trueblood ES; Gosink JJ; Thurman R; Wo S; Spahr K; Haass EJ; Snead K; Miller D; Padilla M; Smith AJ; Frantz C; Schrum JP; Nazarenko N; Gardai SJ
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793853
[TBL] [Abstract][Full Text] [Related]
20. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
Arribas AJ; Gaudio E; Napoli S; Yvon Herbaux CJ; Tarantelli C; Bordone RP; Cascione L; Munz N; Aresu L; Sgrignani J; Rinaldi A; Kwee I; Rossi D; Cavalli A; Zucca E; Stussi G; Stathis A; Sloss C; Davids MS; Bertoni F
bioRxiv; 2023 Nov; ():. PubMed ID: 38014209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
